Catalent to Discuss Data-Driven Approaches for Small Molecule Drug Development at the Controlled Release Society Annual Meeting
Cornell Stamoran, Ph.D., founder of Catalent’s Applied Drug Delivery Institute, has been invited to chair two sessions during the conference. Dr. Stamoran will moderate a discussion analyzing the industry’s response to the COVID-19 pandemic, and will also chair Plenary Session 2, featuring Katherine High, M.D.
In her presentation, titled “Data-Driven Formulation Approaches for Oral Small Molecule Drugs,” Lisa Caralli, Director, Science & Technology, will examine the role of physicochemical and biopharmaceutical data in guiding early small molecule drug development decisions. Ms. Caralli will explain how to apply the developability classification system (DCS) to guide formulation design, relate physiochemical properties to the impact on solubility and bioavailability, and discuss the importance of physiologically-based pharmacokinetic (PBPK) modeling in ascertaining a molecule’s developability.
During the conference, Catalent will also present the following scientific posters:
- “Calcium Methylfolate Compatibility Studies in Gelatin Capsules,” presented by Tiago Barros, Senior Analyst, Research & Development
- “Quantitation of the Crystalline Phase in Milled Prototype Hot Melt Extrudate Indomethacin Formulations by X-ray Powder Diffraction,” presented by Imre Vitez, Principal Scientist, Physical Pharmaceutics Formulations, Research & Development
- “Evaluation of Ribbon Porosity as an Indicator of Ribbon Properties of Roller Compacted Material,” presented by Priya Batheja, Principal Scientist, Formulations, Research & Development
- “Fast and Flexible Preparation Strategy of Lipid-Based Formulation of Early Phase Clinical Study,” presented by Benoit Hilbold, Product Development Supervisor, Research & Development
Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He also founded and serves as Co-Chair of Catalent’s Applied Drug Delivery Institute (www.drugdeliveryinstitute.com). He has spent more than 30 years engaged with the healthcare industry, including more than 25 years in advanced drug and biologic delivery and outsourcing.
Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with pharmaceutical companies to identify appropriate development pathways for early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals, and began her career at the Immune Response Corporation. Ms. Caralli holds a bachelor’s degree in biochemistry from the University of California at Davis, California.
The presentations will be available to view on-demand through the conference platform.
Notes for Editors
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com